Almaz Sammya, Clément Normand, Nicolas Desbaillets, Mehtap Coskun, Camille Goudemant, Valérie Mosimann, Nabila Ferahta, Melissa Christofis, Andrea Serena, Asteria Nikolopoulou, Karim Abdelhamid, Antonia Stamatiou, Tu Nguyen-Ngoc, Hasna Bouchaab, Mapi Fleury, Michel Obeid, Solange Peters, Nuria Mederos
{"title":"【胸部肿瘤新治疗方法的不良反应】。","authors":"Almaz Sammya, Clément Normand, Nicolas Desbaillets, Mehtap Coskun, Camille Goudemant, Valérie Mosimann, Nabila Ferahta, Melissa Christofis, Andrea Serena, Asteria Nikolopoulou, Karim Abdelhamid, Antonia Stamatiou, Tu Nguyen-Ngoc, Hasna Bouchaab, Mapi Fleury, Michel Obeid, Solange Peters, Nuria Mederos","doi":"10.53738/REVMED.2025.21.918.47240","DOIUrl":null,"url":null,"abstract":"<p><p>The rapid evolution of oncological treatments in patients with lung cancer has led to the emergence of targeted therapies (TT), immune checkpoint inhibitors (ICI), and antibody-drug conjugates (ADC), which are significantly transforming the management of cancer. However, these advances are associated with complex adverse effects that affect multiple organ systems. This review explores the etiopathogenic mechanisms underlying therapy-related toxicity and describes the major adverse effects: immune-related toxicity of ICIs, \"on-target\" and \"off-target\" effects of TTs, and systemic toxicity of ADCs. Systemic toxicities are discussed, with a focus on monitoring strategies and management approaches. A multidisciplinary approach is critical to optimize therapeutic efficacy while minimizing toxicity.</p>","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 918","pages":"1023-1030"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Adverse effects of new therapeutic approaches in thoracic oncology].\",\"authors\":\"Almaz Sammya, Clément Normand, Nicolas Desbaillets, Mehtap Coskun, Camille Goudemant, Valérie Mosimann, Nabila Ferahta, Melissa Christofis, Andrea Serena, Asteria Nikolopoulou, Karim Abdelhamid, Antonia Stamatiou, Tu Nguyen-Ngoc, Hasna Bouchaab, Mapi Fleury, Michel Obeid, Solange Peters, Nuria Mederos\",\"doi\":\"10.53738/REVMED.2025.21.918.47240\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The rapid evolution of oncological treatments in patients with lung cancer has led to the emergence of targeted therapies (TT), immune checkpoint inhibitors (ICI), and antibody-drug conjugates (ADC), which are significantly transforming the management of cancer. However, these advances are associated with complex adverse effects that affect multiple organ systems. This review explores the etiopathogenic mechanisms underlying therapy-related toxicity and describes the major adverse effects: immune-related toxicity of ICIs, \\\"on-target\\\" and \\\"off-target\\\" effects of TTs, and systemic toxicity of ADCs. Systemic toxicities are discussed, with a focus on monitoring strategies and management approaches. A multidisciplinary approach is critical to optimize therapeutic efficacy while minimizing toxicity.</p>\",\"PeriodicalId\":21286,\"journal\":{\"name\":\"Revue medicale suisse\",\"volume\":\"21 918\",\"pages\":\"1023-1030\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue medicale suisse\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53738/REVMED.2025.21.918.47240\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue medicale suisse","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53738/REVMED.2025.21.918.47240","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
[Adverse effects of new therapeutic approaches in thoracic oncology].
The rapid evolution of oncological treatments in patients with lung cancer has led to the emergence of targeted therapies (TT), immune checkpoint inhibitors (ICI), and antibody-drug conjugates (ADC), which are significantly transforming the management of cancer. However, these advances are associated with complex adverse effects that affect multiple organ systems. This review explores the etiopathogenic mechanisms underlying therapy-related toxicity and describes the major adverse effects: immune-related toxicity of ICIs, "on-target" and "off-target" effects of TTs, and systemic toxicity of ADCs. Systemic toxicities are discussed, with a focus on monitoring strategies and management approaches. A multidisciplinary approach is critical to optimize therapeutic efficacy while minimizing toxicity.
期刊介绍：
Destinée aux professionnels de santé, la plateforme revmed.ch regroupe la version électronique de la Revue Médicale Suisse et les applications de formation et d"aide à la prise de décision eRMS. La eRMS est le fruit d’une large collaboration entre institutions et praticiens de Suisse romande.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
